Source comparison
Muscle Growth Peptides 2026 Update: Protocol Comparison
IGF-1 LR3 Direct IGF-1 receptor agonist, extended half-life 80–100mcg 4× daily (morning, pre-workout, post-workout, pre-bed) 16–20% Requires leucine co-administration; receptor downregulation after 12–16 weeks MGF (PEG-MGF) Localised IGF-1 splice variant, para
This comparison does not assign a generated winner or score.
- IGF-1 LR3
- Direct IGF-1 receptor agonist, extended half-life
- 80–100mcg
- 4× daily (morning, pre-workout, post-workout, pre-bed)
- 16–20%
- Requires leucine co-administration; receptor downregulation after 12–16 weeks
- MGF (PEG-MGF)
- Localised IGF-1 splice variant, paracrine signalling
- 200mcg
- Post-workout only (trained muscles)
- 8–12% (localised hypertrophy in trained groups)
- Systemic effects minimal; best for targeted muscle growth
- GHRP-6
- Stimulates endogenous GH release via ghrelin receptor
- 150–200mcg
- 3× daily (fasted state required)
- 6–10%
- Delayed onset (8–12 weeks); less effective in older adults (>45) with blunted GH response
- Hexarelin
- Potent GHRP with additional cortisol-suppressing effects
- 100mcg
- 2× daily (morning, pre-bed)
- 7–11%
- Desensitisation occurs rapidly (6–8 weeks); requires 4-week washout between cycles
- TB-500 (Thymosin Beta-4)
- Promotes satellite cell migration and angiogenesis
- 2–2.5mg
- 2× weekly
- 3–5% (indirect via recovery enhancement)
- Not a direct anabolic. Supports hypertrophy through injury recovery and workload capacity
- BPC-157
- Enhances collagen synthesis, tendon repair, GH receptor upregulation
- 250–500mcg
- 1–2× daily (injection site near injury or systemic)
- 2–4% (indirect via training volume tolerance)
- Mechanism not fully characterised; effects highly individual